team members

Keith Gottesdiener

MD

President and CEO

Keith Gottesdiener, MD is President and Chief Executive Officer of Prime Medicine and has served as a member of our Board of Directors since July 2020.

From October 2011 until March 2020, Dr. Gottesdiener served as the Chief Executive Officer and a director of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company that develops therapeutics in rare genetic obesity. During that time, Rhythm submitted a New Drug Application for setmelanotide in two indications, for which setmelanotide was subsequently approved.

Dr. Gottesdiener joined Rhythm after 16 years at Merck Research Laboratories, where, starting in 1995, he held positions of increasing responsibility, including serving as a leader of Merck’s late clinical development organization from 2006 to 2011 and leading Merck’s early clinical development across all therapeutic areas from 2001 through early 2006. In such roles, Dr. Gottesdiener oversaw, led, or played a lead role in the development of most of Merck’s approved therapeutics and vaccines.

Dr. Gottesdiener received his B.A. from Harvard College and his M.D. from the University of Pennsylvania. He completed his residency and fellowship at the Brigham and Women’s Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children’s Hospital programs. After his fellowship, Dr. Gottesdiener did postdoctoral research in the laboratory of Dr. Jack Strominger at the Dana Farber Cancer Institute. He then joined the faculty as an assistant professor at Columbia University, where he started an independent research laboratory with NIH RO-1 funding, ending his academic career as Associate Clinical Professor of Medicine at the time he left to join Merck in 1995.

Dr. Gottesdiener is also a director at Intercept Pharmaceutics, and at Cardurion Pharmaceuticals.